Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder
The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been publi...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2020-03, Vol.21 (6), p.2148 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 2148 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Kang, Seung-Gul Cho, Seo-Eun |
| description | The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD. |
| doi_str_mv | 10.3390/ijms21062148 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7139562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2386280457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-9eaefb1904c38ec287fc8b1cda31b3d050b929e13020b9967775ee91ed7a0a743</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS1URJeFW89VpF44sOCPJLYvlcq2BaTlQ2g5W44z2TpN4u04qcR_j1e7VFtOM6P5zdM8PULOGP0ghKYffdtHzmjJWa5ekBnLOV9QWsqTo_6UvI6xpZQLXuhX5FRwnhdUlTMC32HC4Hu78cMm--RDb_EeMGZNwOwnQu3duNusEezYwzBmvyBuwxAhs0OdBjchwuAgC032zbbp6hq2CDH6R8iufQxYA74hLxvbRXh7qHPy-_ZmvfyyWP34_HV5tVq4XKpxocFCUzFNcycUOK5k41TFXG0Fq0RNC1pproEJylOnSyllAaAZ1NJSK3MxJ5d73e1U9VC79C_azmwxGcQ_Jlhvnm8Gf2c24dFIJnRR8iTw7iCA4WGCOJreRwddZwcIUzRcqJIrmhcyoRf_oW2YcEj2dhRXSglGE_V-TzkMMSI0T88wanb5meP8En5-bOAJ_heY-As3SJhW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382888310</pqid></control><display><type>article</type><title>Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kang, Seung-Gul ; Cho, Seo-Eun</creator><creatorcontrib>Kang, Seung-Gul ; Cho, Seo-Eun</creatorcontrib><description>The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21062148</identifier><identifier>PMID: 32245086</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Accuracy ; Antidepressants ; Biomarkers ; Biomarkers - metabolism ; Brain research ; Computed tomography ; Depressive Disorder, Major - diagnostic imaging ; Depressive Disorder, Major - genetics ; Depressive Disorder, Major - therapy ; Electroconvulsive therapy ; Emotional behavior ; Functional magnetic resonance imaging ; Genomes ; Humans ; Infrared imaging ; Infrared spectra ; Infrared spectroscopy ; Insomnia ; Machine Learning ; Magnetic resonance imaging ; Magnetic resonance spectroscopy ; Medical imaging ; Mental depression ; Mental disorders ; Near infrared radiation ; Neuroimaging ; Patients ; Photon emission ; Physicians ; Positron emission ; Positron emission tomography ; Precision medicine ; Recurrence ; Review ; Single photon emission computed tomography ; Sleep ; Spectrum analysis ; Studies ; Systematic review</subject><ispartof>International journal of molecular sciences, 2020-03, Vol.21 (6), p.2148</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-9eaefb1904c38ec287fc8b1cda31b3d050b929e13020b9967775ee91ed7a0a743</citedby><cites>FETCH-LOGICAL-c478t-9eaefb1904c38ec287fc8b1cda31b3d050b929e13020b9967775ee91ed7a0a743</cites><orcidid>0000-0003-4933-0433</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139562/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139562/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32245086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Seung-Gul</creatorcontrib><creatorcontrib>Cho, Seo-Eun</creatorcontrib><title>Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD.</description><subject>Accuracy</subject><subject>Antidepressants</subject><subject>Biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Brain research</subject><subject>Computed tomography</subject><subject>Depressive Disorder, Major - diagnostic imaging</subject><subject>Depressive Disorder, Major - genetics</subject><subject>Depressive Disorder, Major - therapy</subject><subject>Electroconvulsive therapy</subject><subject>Emotional behavior</subject><subject>Functional magnetic resonance imaging</subject><subject>Genomes</subject><subject>Humans</subject><subject>Infrared imaging</subject><subject>Infrared spectra</subject><subject>Infrared spectroscopy</subject><subject>Insomnia</subject><subject>Machine Learning</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic resonance spectroscopy</subject><subject>Medical imaging</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Near infrared radiation</subject><subject>Neuroimaging</subject><subject>Patients</subject><subject>Photon emission</subject><subject>Physicians</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Precision medicine</subject><subject>Recurrence</subject><subject>Review</subject><subject>Single photon emission computed tomography</subject><subject>Sleep</subject><subject>Spectrum analysis</subject><subject>Studies</subject><subject>Systematic review</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1v1DAQxS1URJeFW89VpF44sOCPJLYvlcq2BaTlQ2g5W44z2TpN4u04qcR_j1e7VFtOM6P5zdM8PULOGP0ghKYffdtHzmjJWa5ekBnLOV9QWsqTo_6UvI6xpZQLXuhX5FRwnhdUlTMC32HC4Hu78cMm--RDb_EeMGZNwOwnQu3duNusEezYwzBmvyBuwxAhs0OdBjchwuAgC032zbbp6hq2CDH6R8iufQxYA74hLxvbRXh7qHPy-_ZmvfyyWP34_HV5tVq4XKpxocFCUzFNcycUOK5k41TFXG0Fq0RNC1pproEJylOnSyllAaAZ1NJSK3MxJ5d73e1U9VC79C_azmwxGcQ_Jlhvnm8Gf2c24dFIJnRR8iTw7iCA4WGCOJreRwddZwcIUzRcqJIrmhcyoRf_oW2YcEj2dhRXSglGE_V-TzkMMSI0T88wanb5meP8En5-bOAJ_heY-As3SJhW</recordid><startdate>20200320</startdate><enddate>20200320</enddate><creator>Kang, Seung-Gul</creator><creator>Cho, Seo-Eun</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4933-0433</orcidid></search><sort><creationdate>20200320</creationdate><title>Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder</title><author>Kang, Seung-Gul ; Cho, Seo-Eun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-9eaefb1904c38ec287fc8b1cda31b3d050b929e13020b9967775ee91ed7a0a743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Accuracy</topic><topic>Antidepressants</topic><topic>Biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Brain research</topic><topic>Computed tomography</topic><topic>Depressive Disorder, Major - diagnostic imaging</topic><topic>Depressive Disorder, Major - genetics</topic><topic>Depressive Disorder, Major - therapy</topic><topic>Electroconvulsive therapy</topic><topic>Emotional behavior</topic><topic>Functional magnetic resonance imaging</topic><topic>Genomes</topic><topic>Humans</topic><topic>Infrared imaging</topic><topic>Infrared spectra</topic><topic>Infrared spectroscopy</topic><topic>Insomnia</topic><topic>Machine Learning</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic resonance spectroscopy</topic><topic>Medical imaging</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Near infrared radiation</topic><topic>Neuroimaging</topic><topic>Patients</topic><topic>Photon emission</topic><topic>Physicians</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Precision medicine</topic><topic>Recurrence</topic><topic>Review</topic><topic>Single photon emission computed tomography</topic><topic>Sleep</topic><topic>Spectrum analysis</topic><topic>Studies</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Seung-Gul</creatorcontrib><creatorcontrib>Cho, Seo-Eun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Seung-Gul</au><au>Cho, Seo-Eun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-03-20</date><risdate>2020</risdate><volume>21</volume><issue>6</issue><spage>2148</spage><pages>2148-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32245086</pmid><doi>10.3390/ijms21062148</doi><orcidid>https://orcid.org/0000-0003-4933-0433</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2020-03, Vol.21 (6), p.2148 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7139562 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Accuracy Antidepressants Biomarkers Biomarkers - metabolism Brain research Computed tomography Depressive Disorder, Major - diagnostic imaging Depressive Disorder, Major - genetics Depressive Disorder, Major - therapy Electroconvulsive therapy Emotional behavior Functional magnetic resonance imaging Genomes Humans Infrared imaging Infrared spectra Infrared spectroscopy Insomnia Machine Learning Magnetic resonance imaging Magnetic resonance spectroscopy Medical imaging Mental depression Mental disorders Near infrared radiation Neuroimaging Patients Photon emission Physicians Positron emission Positron emission tomography Precision medicine Recurrence Review Single photon emission computed tomography Sleep Spectrum analysis Studies Systematic review |
| title | Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T00%3A23%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroimaging%20Biomarkers%20for%20Predicting%20Treatment%20Response%20and%20Recurrence%20of%20Major%20Depressive%20Disorder&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Kang,%20Seung-Gul&rft.date=2020-03-20&rft.volume=21&rft.issue=6&rft.spage=2148&rft.pages=2148-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21062148&rft_dat=%3Cproquest_pubme%3E2386280457%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2382888310&rft_id=info:pmid/32245086&rfr_iscdi=true |